Last reviewed 2026-04-20 · How we verify

DURLOBACTAM SODIUM

FDA-approved approved Small molecule Quality 2/100

DURLOBACTAM SODIUM is a drug. It is currently FDA-approved (first approved 2023).

Durlobactam Sodium is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	DURLOBACTAM SODIUM
Modality	Small molecule
Phase	FDA-approved
First approval	2023

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DURLOBACTAM SODIUM CI brief — competitive landscape report
DURLOBACTAM SODIUM updates RSS · CI watch RSS

Frequently asked questions about DURLOBACTAM SODIUM

What is DURLOBACTAM SODIUM?

DURLOBACTAM SODIUM is a Small molecule drug.

When was DURLOBACTAM SODIUM approved?

DURLOBACTAM SODIUM was first approved on 2023.

What development phase is DURLOBACTAM SODIUM in?

DURLOBACTAM SODIUM is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing